Here we show that ZIKV treatment remodels the GBM microenvironment and supports a CD8+ T cell infiltrative response in the tumor environment, and this is crucial for therapeutic efficacy against both primary and secondary tumors. The gene discussed is CD8A; the disease is glioblastoma.